tradingkey.logo

Rapid Micro Biosystems Inc

RPID
View Detailed Chart
3.870USD
+0.190+5.16%
Close 02/06, 16:00ETQuotes delayed by 15 min
171.48MMarket Cap
LossP/E TTM

Rapid Micro Biosystems Inc

3.870
+0.190+5.16%
Intraday
1m
30m
1h
D
W
M
D

Today

+5.16%

5 Days

-12.64%

1 Month

+14.50%

6 Months

+13.49%

Year to Date

+33.45%

1 Year

+24.84%

View Detailed Chart

Key Insights

Rapid Micro Biosystems Inc's fundamentals are relatively healthy, with an industry-leading ESG disclosure.and its growth potential is significant.Its valuation is considered fairly valued, ranking 98 out of 205 in the Healthcare Equipment & Supplies industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 8.00.In the medium term, the stock price is expected to trend up.Despite strong stock market performance and technicals over the past month, the fundamentals don't support the current trend.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Rapid Micro Biosystems Inc's Score

Industry at a Glance

Industry Ranking
98 / 205
Overall Ranking
261 / 4521
Industry
Healthcare Equipment & Supplies

Support & Resistance

Relevant data have not been disclosed by the company yet.

Score Analysis

Current score
Previous score

Media Coverage

Last 24 hours
Coverage Level

Very Low
Very High
Neutral

Rapid Micro Biosystems Inc Highlights

StrengthsRisks
Rapid Micro Biosystems, Inc. is a life sciences technology company providing mission-critical automation solutions to facilitate the manufacturing and release of healthcare products such as biologics, vaccines, cell and gene therapies, and sterile injectables. Its flagship Growth Direct system automates and modernizes the antiquated, manual microbial quality control (MQC) testing workflows used in pharmaceutical manufacturing operations. It offers four specific applications for testing of microbial contamination: Environmental Monitoring, which tests the manufacturing environment, including circulating air, exposed surfaces, and personnel; Water, which tests any purified water used at any stage of the drug production process, including water for injection; In-Process Bioburden, which tests raw materials, drug substance and in-process product, and Sterility Release offering final testing of finished product to ensure sterility before the product is released for commercial sale.
High Growth
The company's revenue has grown steadily over the past 3 years, averaging 63.72% year-on-year.
Growing
The company is in a growing phase, with the latest annual income totaling USD 28.05M.
Undervalued
The company’s latest PE is -3.88, at a low 3-year percentile range.
Institutional Selling
The latest institutional holdings are 23.36M shares, decreasing 7.42% quarter-over-quarter.
Held by The Vanguard
Star Investor The Vanguard holds 978.78K shares of this stock.

Analyst Rating

Based on 4 analysts
Buy
Current Rating
8.000
Target Price
+117.39%
Upside Space
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Rapid Micro Biosystems Inc News

More news coming soon, stay tuned...

Financial Indicators

EPS

Relevant data have not been disclosed by the company yet.

Total revenue

Relevant data have not been disclosed by the company yet.

Rapid Micro Biosystems Inc Info

Rapid Micro Biosystems, Inc. is a life sciences technology company providing mission-critical automation solutions to facilitate the manufacturing and release of healthcare products such as biologics, vaccines, cell and gene therapies, and sterile injectables. Its flagship Growth Direct system automates and modernizes the antiquated, manual microbial quality control (MQC) testing workflows used in pharmaceutical manufacturing operations. It offers four specific applications for testing of microbial contamination: Environmental Monitoring, which tests the manufacturing environment, including circulating air, exposed surfaces, and personnel; Water, which tests any purified water used at any stage of the drug production process, including water for injection; In-Process Bioburden, which tests raw materials, drug substance and in-process product, and Sterility Release offering final testing of finished product to ensure sterility before the product is released for commercial sale.
Ticker SymbolRPID
CompanyRapid Micro Biosystems Inc
CEOSpignesi (Robert)
Websitehttps://www.rapidmicrobio.com/
KeyAI